OBM transplantation最新文献_第2页

Management of Steatosis in Living Donors: Where Do We Stand? 活体捐献者的脂肪变性管理：我们的现状如何？

OBM transplantation Pub Date : 2024-04-01 DOI: 10.21926/obm.transplant.2402210

Abhideep Chaudhary, Anish Gupta, Imtiakum Jamir, Niteen Kumar, Gaurav Sood

{"title":"Management of Steatosis in Living Donors: Where Do We Stand?","authors":"Abhideep Chaudhary, Anish Gupta, Imtiakum Jamir, Niteen Kumar, Gaurav Sood","doi":"10.21926/obm.transplant.2402210","DOIUrl":"https://doi.org/10.21926/obm.transplant.2402210","url":null,"abstract":"With the progressive rise in rates of liver transplantation, stagnant donor pool, and social factors, living donor liver transplantation (LDLT) forms the majority of liver transplantations performed in Asian countries. As the global prevalence of metabolic-associated fatty liver disease (MAFLD) is increasing, around 17-25% of all the prospective donors turn out to be steatotic at the time of evaluation and, as such, rejected for donor hepatectomy, thereby considerably reducing the living donor pool. Steatotic grafts are a risk factor to both the recipient (primary nonfunction, delayed graft function, and mortality) and the donor (poor regeneration, higher blood loss, and prolonged hospital stay). Weight reduction and dietary optimization have been known to be associated with improvement in steatosis, and multiple interventions have been used in the past to reduce steatosis in these donors and be able to convert these donors from marginal steatotic donors to normal or low-risk donors and utilize these grafts. Most of these studies indicated the efficacy of these optimization protocols. They suggested similar outcomes in these previously steatotic donors compared to donors without steatosis at baseline, but these optimization protocols lack uniformity. This review article aims to highlight the rising prevalence of steatosis in living liver donors, assess the literature on pre-operative management options for steatosis donors, and study the efficacy, safety, and feasibility of these management options.","PeriodicalId":92826,"journal":{"name":"OBM transplantation","volume":"690 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140782402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Airway Complications after Lung Transplantation 肺移植后的气道并发症

OBM transplantation Pub Date : 2024-03-27 DOI: 10.21926/obm.transplant.2401209

Syed Nazeer Mahmood, Amit Mahajan

引用次数: 0

Calculated Human Leucocyte Antigens Evolutionary Divergence (cHED) 计算的人类白细胞抗原进化差异 (cHED)

OBM transplantation Pub Date : 2024-03-11 DOI: 10.21926/obm.transplant.2401208

Bruno A Lima

引用次数: 0

Chronic Lung Allograft Dysfunction, a Review in 2023 慢性肺移植功能障碍，2023 年回顾

OBM transplantation Pub Date : 2024-02-20 DOI: 10.21926/obm.transplant.2401207

Onix Cantres Fonseca, S. Aryal, Christopher King, Steven Nathan

引用次数: 0

Evaluation of Total Parenteral Nutrition in the Autologous Transplantation Setting in Patients with AML: A Retrospective Exploratory Analysis 评估急性髓细胞性白血病患者自体移植过程中的全肠外营养：回顾性探索分析

OBM transplantation Pub Date : 2024-02-04 DOI: 10.21926/obm.transplant.2401206

Sarah Willi, Ulrike Bacher, M. Kronig, M. Daskalakis, Lia Bally, Thomas Pabst

{"title":"Evaluation of Total Parenteral Nutrition in the Autologous Transplantation Setting in Patients with AML: A Retrospective Exploratory Analysis","authors":"Sarah Willi, Ulrike Bacher, M. Kronig, M. Daskalakis, Lia Bally, Thomas Pabst","doi":"10.21926/obm.transplant.2401206","DOIUrl":"https://doi.org/10.21926/obm.transplant.2401206","url":null,"abstract":"Malnutrition remains a clinical challenge in AML patients undergoing autologous hematopoietic stem cell transplantation (ASCT), leading to physical deconditioning and prolonged hospitalization. Prospective data are mainly lacking to identify those patients who may particularly benefit from parenteral nutrition in this setting. This observational, non-randomized, retrospective, exploratory cohort study assessed the nutritional development in patients following high-dose chemotherapy (HDCT) with ASCT and explored their survival outcomes. The study included all consecutive AML patients who underwent HDCT with ASCT at a single academic center between January 2000 and January 2019. Patients were divided into two primary cohorts: those who received TPN following high-dose chemotherapy and ASCT and those who did not. We identified 126 patients with AML in first complete remission undergoing ASCT consolidation, including 75 patients receiving TPN after HDCT and ASCT and 51 patients without TPN. Neither group differed in gender, age, or subgroups of AML. The nutritional condition at first diagnosis and after induction chemotherapy was equal in both groups, as were median weight changes throughout the induction chemotherapy cycles. Finally, progression-free and overall survival rates were comparable in both groups. Our data suggest that the need to provide TPN for an average of 11 days following HDCT with ASCT for consolidation of first remission in AML patients does not affect the clinical outcome of these patients.","PeriodicalId":92826,"journal":{"name":"OBM transplantation","volume":"34 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139866797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Total Parenteral Nutrition in the Autologous Transplantation Setting in Patients with AML: A Retrospective Exploratory Analysis 评估急性髓细胞性白血病患者自体移植过程中的全肠外营养：回顾性探索分析

OBM transplantation Pub Date : 2024-02-04 DOI: 10.21926/obm.transplant.2401206

Sarah Willi, Ulrike Bacher, M. Kronig, M. Daskalakis, Lia Bally, Thomas Pabst

{"title":"Evaluation of Total Parenteral Nutrition in the Autologous Transplantation Setting in Patients with AML: A Retrospective Exploratory Analysis","authors":"Sarah Willi, Ulrike Bacher, M. Kronig, M. Daskalakis, Lia Bally, Thomas Pabst","doi":"10.21926/obm.transplant.2401206","DOIUrl":"https://doi.org/10.21926/obm.transplant.2401206","url":null,"abstract":"Malnutrition remains a clinical challenge in AML patients undergoing autologous hematopoietic stem cell transplantation (ASCT), leading to physical deconditioning and prolonged hospitalization. Prospective data are mainly lacking to identify those patients who may particularly benefit from parenteral nutrition in this setting. This observational, non-randomized, retrospective, exploratory cohort study assessed the nutritional development in patients following high-dose chemotherapy (HDCT) with ASCT and explored their survival outcomes. The study included all consecutive AML patients who underwent HDCT with ASCT at a single academic center between January 2000 and January 2019. Patients were divided into two primary cohorts: those who received TPN following high-dose chemotherapy and ASCT and those who did not. We identified 126 patients with AML in first complete remission undergoing ASCT consolidation, including 75 patients receiving TPN after HDCT and ASCT and 51 patients without TPN. Neither group differed in gender, age, or subgroups of AML. The nutritional condition at first diagnosis and after induction chemotherapy was equal in both groups, as were median weight changes throughout the induction chemotherapy cycles. Finally, progression-free and overall survival rates were comparable in both groups. Our data suggest that the need to provide TPN for an average of 11 days following HDCT with ASCT for consolidation of first remission in AML patients does not affect the clinical outcome of these patients.","PeriodicalId":92826,"journal":{"name":"OBM transplantation","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139807016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acknowledgement to Reviewers of OBM Transplantation in 2023 鸣谢《2023 年的 OBM 移植》审稿人

OBM transplantation Pub Date : 2024-01-04 DOI: 10.21926/obm.transplant.2401205

Obm Transplantation Editorial Office

引用次数: 0

Immune-Suppression Modulation in Solid Organ Transplant Recipients Admitted for COVID-19 因 COVID-19 而入院的实体器官移植受者的免疫抑制调节

OBM transplantation Pub Date : 2023-12-01 DOI: 10.21926/obm.transplant.2304204

F. Peracchi, G. Travi, Marco Merli, R. Rossotti, Fulvio Crippa, Massimo Puoti

{"title":"Immune-Suppression Modulation in Solid Organ Transplant Recipients Admitted for COVID-19","authors":"F. Peracchi, G. Travi, Marco Merli, R. Rossotti, Fulvio Crippa, Massimo Puoti","doi":"10.21926/obm.transplant.2304204","DOIUrl":"https://doi.org/10.21926/obm.transplant.2304204","url":null,"abstract":"SARS-CoV-2 infection has significantly impacted solid organ transplant (SOT) recipients, who are at high risk of disease and worse outcomes. Moreover, therapeutic management in this population is not precise yet. Our study aimed to evaluate the overall survival of SOT recipients and predictive factors for mortality. We also aimed to assess the impact of antiviral treatments and immunosuppressant changes on overall mortality and to evaluate the length of hospital stay of SOT compared to the general population. This is a retrospective monocenter study. We included all SOT recipients with laboratory-confirmed SARS-CoV2 infection admitted at Niguarda Hospital in Milan from February 2020 through January 2022. We enrolled 74 solid organ transplant recipients with a median age of 59. The overall mortality rate was 19%. Older age, male sex, diabetes, and high LDH values were associated with an increasing fatality rate. The median length of stay (LoS) was 17 days. Low white blood count and lymphocyte levels were associated with 19 days LoS. Changes in immunosuppression and SARS-CoV-2 antiviral therapies had no impact on mortality and LoS. In this study, we confirm previously described risk factors for worse outcomes. We did not observe beneficial therapies in terms of mortality rate and LoS. Seven patients received antiviral treatment. More studies are needed to assess the best therapeutical options, including immunosuppressant modulation, in SOTs.","PeriodicalId":92826,"journal":{"name":"OBM transplantation","volume":" 928","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138610437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung Donor Selection and Management: An Updated Review 肺捐献者的选择与管理：最新回顾

OBM transplantation Pub Date : 2023-11-23 DOI: 10.21926/obm.transplant.2304203

Shefali Mody, Soham Nadkarni, Shreyash Vats, Akshay Kumar, Sravanthi Nandavaram, Suresh Keshavamurthy

引用次数: 0

Acute Rejection of the Lung Allograft: Phenotypes and Management 肺移植的急性排斥反应：表型与管理

OBM transplantation Pub Date : 2023-11-21 DOI: 10.21926/obm.transplant.2304202

Brandon Menachem, Sandrine Hanna, Deepika Kulkarni, Hakim Azfar Ali

{"title":"Acute Rejection of the Lung Allograft: Phenotypes and Management","authors":"Brandon Menachem, Sandrine Hanna, Deepika Kulkarni, Hakim Azfar Ali","doi":"10.21926/obm.transplant.2304202","DOIUrl":"https://doi.org/10.21926/obm.transplant.2304202","url":null,"abstract":"Treatment options for end stage lung diseases are limited to stabilizing lung failure, decreasing disease progression, and symptom management, but significant reversal of lost lung function is often not possible. For well selected patients, lung transplantation may be a viable option to improve both longevity and quality of life. Though outcomes for lung transplant recipients have improved over several decades, long term survival still lags behind that of other solid organ transplant recipients. Longevity after lung transplantation is limited by chronic lung allograft dysfunction. Numerous insults to the allograft contribute to chronic rejection, alloimmune injuries including acute T-cell mediated and antibody mediated rejection are chief among them. Therefore, monitoring for and management of acute cellular and antibody mediated rejection are of paramount importance to those caring for lung transplant recipients. We provide an up to date and comprehensive review of acute rejection affecting lung allografts and attempt to highlight pathophysiology, risk factors, clinical presentation, rejection phenotypes, management strategies, as well as related from of acute allograft injury.","PeriodicalId":92826,"journal":{"name":"OBM transplantation","volume":"87 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0